STOCK TITAN

ESSA Pharma Inc. - $EPIX STOCK NEWS

Welcome to our dedicated page for ESSA Pharma news (Ticker: $EPIX), a resource for investors and traders seeking the latest updates and insights on ESSA Pharma stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ESSA Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ESSA Pharma's position in the market.

Rhea-AI Summary
ESSA Pharma presents updated Phase 1 masofaniten (EPI-7386) clinical data at the European Society of Medical Oncology 2023 Congress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
ESSA Pharma initiates Phase 2 study evaluating masofaniten in combination with enzalutamide for prostate cancer treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.91%
Tags
-
Rhea-AI Summary
ESSA Pharma Inc. has announced that its President and CEO, David R Parkinson, and its EVP and COO, Peter Virsik, have established Automatic Securities Disposition Plans (ASDPs) in accordance with securities legislation. The ASDPs allow for the sale of up to 808,333 common shares of ESSA over the course of approximately 24 months, starting on January 5, 2024. The sales will be made at prevailing market prices and will commence after the filing of the Form 10-K with the SEC for the fiscal year ending September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
management
-
Rhea-AI Summary
ESSA Pharma to present at 2023 Jefferies Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.43%
Tags
conferences
-
Rhea-AI Summary
ESSA Pharma Inc. has entered into a clinical trial support agreement with Janssen to supply Erleada® and Zytiga® for a Phase 1 study of EPI-7386 combination therapies. They also continue to enroll patients in the Phase 1 EPI-7386 combination study with Xtandi® and expect to complete Phase 1 in 3Q2023. Additionally, the Phase 1b EPI-7386 monotherapy expansion study is ongoing. ESSA is in a strong cash position and expects to fund operations through 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.05%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.71%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.82%
Tags
ESSA Pharma Inc.

Nasdaq:EPIX

EPIX Rankings

EPIX Stock Data

304.36M
24.60M
2.27%
78.66%
1.81%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
VANCOUVER

About EPIX

as a clinical-stage pharmaceutical company founded on cutting-edge research, essa is focused on developing novel therapeutics for cancer patients. essa embraces innovation not only in our products but also in our approach. we're firmly rooted in creative and open thinking, giving us an energy and approach that makes us a different kind of pharmaceutical company.